Viking Therapeutics Positions Itself as a Major Contender in Weight-Loss Market

Viking Therapeutics advances oral obesity drug VK2735 into Phase 3, secures massive manufacturing deal, and targets 5-10% global market share with a $706M cash reserve.

The pharmaceutical landscape for weight management is currently controlled by a handful of industry giants. Viking Therapeutics is now emerging as a formidable competitor, bolstered by recent regulatory progress and significant manufacturing preparations. With the U.S. Food and Drug Administration (FDA) clearing the path for an oral version of its lead drug candidate and a substantial production agreement in place, the biotech firm is gearing up for its next critical phase.

Strategic Manufacturing and Market Ambitions

A key pillar of Viking's strategy involves securing production capacity well ahead of potential commercialization. The company has entered into a multi-year agreement with contract manufacturer CordenPharma to enable large-scale production. The ambitious plan includes manufacturing 100 million auto-injectors annually, alongside one billion tablets of the oral formulation. To lock in these exclusive capacities, Viking Therapeutics is committing substantial capital, with upfront payments totaling $150 million scheduled through 2028.

Management recently outlined its long-term goal of capturing five to ten percent of the global market share, with a particular strategic emphasis on regions outside the United States.

Clinical Pipeline Advances with Oral Formulation in Focus

Progress in the clinical development of the GLP-1/GIP agonist, VK2735, continues to accelerate. Patient recruitment for the subcutaneous version's Phase 3 program, VANQUISH-1, involving approximately 4,650 participants, is already complete. However, the company's oral tablet variant is drawing significant attention. Following constructive discussions with the FDA, Viking plans to initiate its Phase 3 trial for the oral formulation in the third quarter of 2026.

This move carries strategic weight: the oral program is designed to require 75% fewer patients than the injectable studies, representing a substantially more cost-efficient pathway. This decision is supported by compelling Phase 2 data, which demonstrated weight reduction of up to 14.7%.

Financial Health and Insider Confidence

The market has responded positively to this operational momentum. Viking's share price has advanced more than 16% since the release of its annual figures, despite reporting a larger-than-anticipated fourth-quarter loss of $1.38 per share. The company maintains a robust financial cushion of $706 million in cash, providing ample runway to fund expensive registration studies.

Adding a signal of internal confidence, Chief Commercial Officer Neil Aubuchon purchased a block of 4,475 company shares on Tuesday. Beyond its flagship VK2735 program, Viking is concurrently advancing a separate obesity treatment program based on Amylin, for which it expects to soon file an application to begin clinical trials.

A Tightly Scheduled Roadmap

The coming months feature a packed timeline. Later in 2026, Viking anticipates the launch of the oral Phase 3 study and results from ongoing maintenance trials. The company projects that the pivotal registration data for the entire VK2735 program will become available in 2027.